Foralumab Drug Asset Due Diligence Report 2026

This Foralumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Foralumab can convert its Monoclonal antibody profile and CD3ε biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Foralumab (query alias: Foralumab)
Modality / target	Monoclonal antibody; CD3ε; CD3ε inhibitors, Immunomodulators
Highest global status	Phase 2
Originator	NovImmune SA
Active developers	Tiziana Life Sciences Ltd. (Bermuda), Bristol Myers Squibb Co., NovImmune SA

The MCP disease footprint includes Amyotrophic Lateral Sclerosis, Alzheimer Disease, Multiple System Atrophy. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07688239	Phase 2	Not yet recruiting	44	Primary endpoint not disclosed in English source
NCT06890923	Phase 2	Recruiting	55	Primary endpoint not disclosed in English source
NCT06879067	Phase 1	Completed	27	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer’s Patient Treated with Intranasal Foralumab

Phase 2; n=1; evaluation: Positive. Reported fields: Efficacy = showing a marked reduction in microglia activation

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Not Applicable; n=10; evaluation: Positive. Reported fields: TRSAE = None

Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab

Not Applicable; n=not disclosed; evaluation: Positive. Reported fields: clinical improvement(PET imaging) = 80 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Foralumab addresses Amyotrophic Lateral Sclerosis, Alzheimer Disease, Multiple System Atrophy. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-09-02	Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment	Phase 2	Financial terms not disclosed
2014-12-22	Tiziana Life Sciences Plc Licenses Foralumab From NovImmune SA	Phase 2	US$1.2M upfront
2005-01-01	Serono and NovImmune S.A. entered into an exclusive worldwide agreement	Not disclosed	US$5.0M upfront; US$105.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Therapies for preventing or treating inflammatory eye disease”. The milestone feed surfaced a patent-application signal described as “Combinations of foralumab with glucagon-like peptide 1 (GLP-1) agonists or sodium-glucose cotransporter-2 (SGLT2) inhibitors and methods of use thereof”. The milestone feed surfaced a patent-application signal described as “Biopharmaceutical prodrug platform based on protein conformational change”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO